This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

ANNX BTA Stock Overview

A biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. More details

ANNX BTA fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 178.06% per year

Risk Analysis

Shareholders have been substantially diluted in the past year

Makes less than USD$1m in revenue (SEK0)

Shares are highly illiquid

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 1 more risk

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

My Notes

Capture your thoughts, links and company narrative

Annexin Pharmaceuticals AB (publ) Competitors

Cessatech

NGM:CESSA

DKK 163.8m

Pila Pharma

OM:PILA

SEK 92.2m

AlzeCure Pharma

OM:ALZCUR

SEK 297.6m

ODI Pharma

NGM:ODI

SEK 38.5m

Price History & Performance

Summary of share price highs, lows and changes for Annexin Pharmaceuticals
Historical stock prices
Current Share Price	SEK 0.51
52 Week High	SEK 0.54
52 Week Low	SEK 0.26
Beta	1.13
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	88.54%

Recent updates

Shareholder Returns

	ANNX BTA	SE Pharmaceuticals	SE Market
7D	10.9%	-9.1%	-1.5%
1Y	n/a	-3.8%	3.3%

Return vs Industry: Insufficient data to determine how ANNX BTA performed against the Swedish Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how ANNX BTA performed against the Swedish Market.

Price Volatility

Is ANNX BTA's price volatile compared to industry and market?
ANNX BTA volatility
ANNX BTA Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	9.4%
Market Average Movement	6.0%
10% most volatile stocks in SE Market	13.1%
10% least volatile stocks in SE Market	3.4%

Stable Share Price: ANNX BTA's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine ANNX BTA's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2014	4	Anders Haegerstrand	www.annexinpharma.com/sv

Annexin Pharmaceuticals AB (publ), a biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. It develops ANXV, a human recombinant protein. The company offers Annexin A5 to protect and repair blood vessels and counteract inflammation.

Annexin Pharmaceuticals AB (publ) Fundamentals Summary

How do Annexin Pharmaceuticals's earnings and revenue compare to its market cap?
ANNX BTA fundamental statistics
Market cap	SEK 156.66m
Earnings (TTM)	-SEK 46.41m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-3.4x

P/E Ratio

Is ANNX BTA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ANNX BTA income statement (TTM)
Revenue	SEK 0
Cost of Revenue	SEK 0
Gross Profit	SEK 0
Other Expenses	SEK 46.41m
Earnings	-SEK 46.41m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.13
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did ANNX BTA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/06/15 15:39
End of Day Share Price	2024/06/14 00:00
Earnings	2024/03/31
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Annexin Pharmaceuticals AB (publ) is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Fredrik Thor	Redeye

Annexin Pharmaceuticals OM:ANNX BTA Stock Report